To define the impact of a negative BRCAl test result on subsequent breast cancer screening behavior in women. Methods: Longitudinal study of a community-based sample of Ashkenazi Jews offered testing for the 185delAG BRCAl mutation in 1996. Of 309 participants, 118 women were mutation negative, of average risk (based on family history of cancer), unaffected with breast cancer, and provided complete data at baseline, and Year 1 and Year 2 follow-up questionnaires. Approximately one in eight women in the United States eventually will develop breast cancer.' This risk is higher for women of Ashkenazi Jewish ancestry.' Initial studies of mutations in the BRCAl breast cancer susceptibility gene revealed a deleterious founder mutation (185delAG) with a carrier frequency of 1% in the Ashkenazi Jewish pop~lation.',~ This germline mutation is associated with a higher rate and an earlier onset ofboth breast and ovarian ~a n c e r .~~~ Another BRCAl mutation (5382insC) and a BRCA2 mutation (6174delT) were discovered to be frequent in the Ashkenazi population subsequent to the initiation of this s t~d y .~,~ Overall, approximately 1 in 40 Ashkenazi Jews carries one of these three cancer susceptibility mutations.Y.lo
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The identification of breast cancer susceptibility genes provides the opportunity for DNA testing of at-risk individuals. It is important to study the impact of a negative test result on cancer screening behaviors because ( 1 ) the majority of individuals undergoing testing will receive negative test results (in one study, only 18% of a high-risk population tested positive for a mutation in BRCAl or BRCA2I1) and (2) women with negative BRCAl and BRCA2 test results retain a substantial lifetime risk
Fronr the Drp,rrrrricn~s ,I( 'Pr,ir,r~r~c-\, ' t \ I o l~~~~r i l~r r ,rrr<l F l r r~i~~i~r (Gc.~rctic~>, '~\I~~~ircrrrc~. ,rrr<l 'PsycIrrnlry r~rrcl Bekm~rur,rl SL.IL.IICL., Iitlylc>~. of developing breast cancer. It is important to determine whether individuals who receive negative BRCAl or BRCA2 test results continue to follow cancer surveillance guidelines and remain aware that they are still at risk of developing breast cancer. Studying the impact of DNA testing on Ashkenazim is especially relevant, because the frequency of these founder mutations and the lower cost of DNA testing for founder mutations facilitates testing in this population. The purpose of this study was to examine longitudinally the psychological and medical impact of DNA testing for a common mutation, BRCAl 185delAG, in a community-based sample of Ashkenazi Jews. For this analysis, we studied only those participants who received negative test results and did not have significant family histories of cancer. We hypothesized that negative test results would be associated with a decrease in mammography behavior over time. In addition, we examined the impact of other factors on mammography behavior, including breast cancer risk perception, breast cancer worry, and physician recommendation.
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Procedures
A full description of the initial testing portion of this study can be found in Richards et al." The Baylor College of Medicine Institutional Review Board approved the study and informed consent for DNA testing and longitudinal follow-up was obtained after the initial educational session. The study was advertised in the Houston community, including local publications and newsletters of Jewish organizations. Eligibility included all adult men and women of at least 50% Ashkenazi ancestry independent of personal or family history of cancer. People interested in participating were invited to attend 90-minute educational/enrollment sessions held at either Baylor College of Medicine or the Jewish Community Center of Houston. The sessions included a 45-minute slide presentation. The first half covered a number of topics, including a summary of risk factors for breast cancer, breast and ovarian cancer genetics, cancer risk in BRCAl mutation carriers, and the discovery of the 185delAG mutation in the BRCAl gene. The meaning of both a positive and negative mutation test were reviewed as well as recommendations to continue cancer screening guidelines (for breast and colon cancer) for individuals receiving a negative test result. The second half described the goals of the study and reviewed the protocol and informed consent documents. At the end of the session participants who elected to join the study were asked to fill out the questionnaires described below and were offered testing (with disclosure of results) for the 185delAG mutation.
Information with regard to mammography behavior, personal and family cancer histories, doctor recommendation, breast cancer risk perception, and breast cancer worry were obtained by self-administered questionnaires. Questionnaires were filled out at entry prior to testing (baseline) and by mad at 1 month, 6 months, 1 year, and 2 years after receipt oftest results. Testingwith disclosure of results was performed in the Spring of 1996 only for the 185delAG mutation. Negative DNA test results were disclosed by letter, and these participants were advised to follow guidelines for breast cancer screening, which at that time included annual mammograms for women age 50 and older.
Study population
Overall, 12 enrollment sessions were held, resulting in 309 subjects (93% of attendees) electing to participate in the study. As described in detail in Richards et al., 12 this was a well-educated cohort with 45% having college education and 50% some graduate study. For the study reported here, we eliminated from this analysis 37 males, 22 subjects who declined testing or had positive test results for 185delAG, 32 females who reported personal histories of breast cancer at baseline, and 3 who failed to report their year of birth. This left us with 215 participants. Of this group, 203 were defined as average risk based on family history and 12 were defined as increased risk as described below. One hundred ninety-three average-risk women provided responses for mammography behavior, breast cancer worry, and perceived risk at baseline.
Measures
The self-report measures used in the present study at baseline and for each of the follow-up questionnaires included demographic information (age and education), personal and family cancer histories, mammography behavior, physician recommendation of mammography, breast cancer risk perception, and breast cancer worry.
Cancer history
Participants indicated whether they ever had been diagnosed with breast, ovarian, colon or "other" cancers. To assess family cancer history, participants indicated first-and seconddegree relatives who had been diagnosed with breast, ovarian, and/or colon cancer and age at diagnosis. A positive family history for this study was defined as having one first-degree or two second-degree relatives with breast cancer (at least one under age 50) or ovarian cancer. Participants were defined as "average" risk if they did not meet these criteria based on family history.
Mammography behavior
Participants were asked in each follow-up questionnaire if they had a mammogram during the past year (for baseline measure) or since they last filled out the questionnaire (for follow-up questionnaires). Year 1 mammography behavior was considered positive if they answered "yes" to this question at either the 1 month, 6 months, or 1 year follow-up questionnaire.
Physician recommendation of mammography
Participants were asked the following yeslno question at baseline, Year 1, and Year 2, "In the past 12 months, did your doctor recommend that you get the following procedures?" with mammography being the first procedure listed.
Breast cancer worry
Participants were asked, "How much do you worry that you will get breast cancer some day?" with the choices being 1-not at all, 2-a little, 3-somewhat, and 4-a lot.
Breast cancer perceived risk
Participants were asked "What do you think your chances are of getting breast cancer some day?" with the same choices as noted for worry.
Statistical analysis
Repeated measures analysis of variance (RMANOVA, SPSS version 9.0) was conducted to test for no significant change in mammography, breast cancer-specific worry, and perceived risk scores over the 3-year period (baseline and 2 years of follow-up).13 Only records with complete information for the three follow-up periods were used. Logistic regression analysis was conducted to assess the effects of age category (age 50+ vs. age <50), physician recommendation (yes vs. no), and oneunit increases in breast cancer worry and perceived risk scores on the Year 2 questionnaires on the odds of having mammography during the last (second) follow-up period in the study.
Attrition analysis
One hundred ninety-three women provided responses for mammography behavior, breast cancer worry, and perceived risk at baseline. Complete information on these three measures was provided at baseline, Year 1, and Year 2 questionnaires by 
RESULTS
At the time the average-risk participants received their negative test result, they were informed that recommendations for breast cancer surveillance included annual mammography beginning at age 50. Therefore, in this study, we specifically examined mammography behavior of women age 50 and older separately from that of younger women.
Participants were 118 females whose mean age was 51 years (58 below age 50, and 60 age 50 and older) with a range from 26 to 75. These women all provided complete data for mammography, worry, and perceived breast cancer risk at baseline, Year I, and Year 2. RMANOVA results for these three measures are shown in Table 2 . For the older cohort, 91.7% reported having a mammogram in the year prior to entry and 88.3% during Year 1, and 91.7% during Year 2. These differences are not statistically significant. Analysis of the non-Hispanic Caucasian United States population in 1998 shows 69.8% had a mammogram in the past 2 years.14 Thus, for this age group, receipt of a negative BRCAl result did not alter their very high level of compliance with mammography recommendations. This is despite finding that their worry of developing breast cancer (2.68 baseline, 2.30 Year 1, and 2.45 Year 2; P = 0.002) and perceived risk (2.68 baseline, 2.65 Year 1, and 2.58 Year 2; P = 0.027) declined significantly over the 2 years of follow-up. We performed a similar analysis, including all women ( N = 71) for whom we have complete mammography data (but may be missing some worry or risk data), which also reveals a nonsignificant change ( P = 0.469).
Soon after women in our study received their test results (July of 1996), there was substantial re-evaluation of the benefit for routine mammography in women under age 50. The National Cancer Institute convened a consensus paneli5 and in April of 1997 issued new guidelines publicized in many journals including recommendation of mammography every 1 to 2 years for women between ages of 40 and 50. i6-17 Although we did not notify the cohort about these changes, women may I have read about them in the lay literature or received new recommendations for mammography from their personal physicians. Women in our cohort under age 50 significantly increased their mammography behavior from 46.6% at baseline to 56.9% during Year 1 and 65.5% during Year 2 ( P < 0.035). These women also demonstrated a significant decline in perceived risk and worry about breast cancer over the 2 years of follow-up. Analogously, 67 women below age 50 with complete mammography data but potentially missing worry and perceived risk data also had a significant increase in mammography from baseline until the end of follow-up year 2 (P = 0.025).
Of the group below age 50 (N = 58) for which we have complete information, 44 women were between the ages of 40 and 49. Analysis of this subset also showed increases in mammography behavior from 59% at baseline to 68% during Year 1 and 77% during Year 2. Comparison with the non-Hispanic Caucasian United States population from ages 40 to 49 in 1998 demonstrates that 64% had a mammogram in the past 2 years.
Logistic regression analysis with the dependent variable based on having mammography duringyear 2 ( N = 144) demonstrated that age, physician recommendation, worry about developing breast cancer, and perceived risk of developing breast cancer as reported on the Year 2 questionnaires were all statistically significant predictors of mammography (Table 3) . Interestingly, the odds ratios for reporting mammography in Year 2 were 6.9 [95% confidence interval (CI), 2.47-19.271 for women over age 50 (vs.
< 50), 6.2 (95% CI, 2.35-16.36) for women with a physician recommendation (vs. no recommendation), and 3.76 (95% CI, 1.4-10.12) for a one-unit increase on the perceived risk scale but only 0.35 (95% CI, 0.16-0.79) for a one-unit increase on the breast cancer worry scale. There was no significant effect modification (interaction) between any of these factors.
DISCUSSION
In our analysis of longitudinal data from a cohort of average risk Ashkenazi women receiving negative results for BRCAl testing, there was no decline in mammography behavior after receiving the test result. This cohort started out with excellent compliance of 89% for women age 50 and older and continued to have excellent compliance 2 years after receiving test results. The high level at baseline may reflect a bias in women joining the study. Potential biases include that women who volunteered to participate in the study may have higher compliance Odds ratio (OR), standard error (SE), and 9S0/o confidence intervals (CI). Reference category (i.e., odds ratios = 1 ) based on women age (50 without doctor recommendation. Odds ratios for cancer-specific w o r n and perceived risk based on one-unit increase in worry and perceived cancer risk scales.
than the general Ashkenazi population. There does not appear to be selective attrition, as the women for whom we have complete data had similar mammography behavior and breast cancer worry and risk perception at baseline as the overall cohort. Therefore, the concern that a negative test result would result in decline in cancer surveillance methods does not appear justified with regard to mammography screening for breast cancer. In particular, younger women (age <50) in this cohort had a statistically significant increase in mammography. This finding may be a direct impact of participating in our study, learning about the possibility of early-onset breast cancer, and receiving follow-up questionnaires, or it potentially may be a response to changes in nationally publicized recommendations by the National Cancer Institute for increased mammography behavior in women under age 50. Athough a number of investigators have noted that moderate levels of cancer-specific worry appear to be positively correlated with mammography behavior,Ix our cohort did not demonstrate any decline in mammograms even though cancer worry did decline from baseline. This may be because the decline in worry still resulted in the mean score of the cohort in the mildly to moderately worried range. In contrast, logistic regression demonstrated that worry did have a negative impact on mammography behavior. This finding is consistent with the work of Lerman and colleague^^^^^^ who demonstrated that high levels of cancer-specific worry can intrude on surveillance behaviors. Thus, women seen either in the context of genetic counseling or primary care visits who demonstrate high levels of cancer worry may require additional education and counseling to ensure appropriate cancer screening and surveillance.
Overall, this cohort ofwell-educated Ashkenazi women who received negative BRCAl test results still complied with their physicians' recommendations and continued to correctly perceive that they remained at risk of developing breast cancer, necessitating mammography surveillance. One challenge to geneticists and oncologists is ensuring that women who may be less medically sophisticated than our cohort understand these issues as well. For example, in one study, genetic counseling about breast cancer risk resulted in a decrease in mammography behavior for less-educated participants." The need for continued surveillance in women who test negative for breast cancer susceptibility gene mutations is highlighted by the diagnosis of breast cancer in six "average" risk women in the Ashkenazi cohort during the 2 follow-up years of this study.
